Immix Biopharma Inc

NASDAQ IMMX

Download Data

Immix Biopharma Inc Net Income Before Taxes 5 year CAGR for the quarter ending March 31, 2024

Immix Biopharma Inc Net Income Before Taxes 5 year CAGR is NA for the quarter ending March 31, 2024. Net income before taxes represents a company's profit after all operating expenses and interest expenses have been deducted but before taxes have been accounted for. It is calculated by dividing the net income by (1 - tax rate). This metric helps evaluate the company's profitability and assess its earnings before the impact of tax obligations. It provides insights into the company's pre-tax financial performance and is often used for comparing companies in different tax jurisdictions. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Immix Biopharma Inc Net Income Before Taxes for the quarter ending March 31, 2023 was -2,492,862.00, a -87.37% change year over year.
  • Immix Biopharma Inc Net Income Before Taxes for the quarter ending March 31, 2022 was -1,330,426.00, a -31.07% change year over year.
  • Immix Biopharma Inc Net Income Before Taxes for the quarter ending March 31, 2021 was -1,015,064.00.
NASDAQ: IMMX

Immix Biopharma Inc

CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date Dec. 16, 2021
Location United States
Headquarters 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

AVRO

AVROBIO Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email